Figure 5.
Dose-Dependent Augmentation of CAR T Cell Proliferation and Antitumor Efficacy of dnTGF-βRII CAR T Cells Compared to PSMA CAR T Cells In Vivo
Systemic PC3-PSMA tumors were established from intravenous (i.v.) infusions with the timeline described in (A), with varied doses of 0.5 × 106 and 2.5 × 106 CAR T cells per mouse infused 2 weeks later. Mice were assessed with BLI weekly to assess tumor burden (B). Body weight of the groups of mice is shown in (C). Images of this BLI assessment are shown to demonstrate location and burden of tumors (D). Mice were bled at days 33 and 64 to assess the amounts of human CD3 T cells within the blood of these mice (E) (n = 5 mice/group). The error bars represent ± SD. *p < 0.05 and ***p < 0.001.